Kite Pharma
TECARTUS
Manufacturer:
Kite Pharma
Name:
TECARTUS
HCPCS Code Descriptor:
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2053
NDC(s):
71287-0220-01, 71287-0219-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
TECARTUS is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2053 is aligned to the drug TECARTUS.